Fibrin, one of the components of the extracellular matrix (ECM), acts as a transport barrier
within the core of tumors by constricting the blood vessels and forming clots, leading to poor …

The use of thrombolytic therapies is limited by an increased risk of systemic hemorrhage due
to lysis of hemostatic clots. We sought to develop a plasmin-based thrombolytic nanocage …

Elevated interstitial fluid pressure and solid stress within tumors contribute to poor
intratumoral distribution of nanomedicine. In this study, we hypothesized that the presence of …

Conspectus The past decades have witnessed the development of a field dedicated to
targeting tumor vasculature for cancer therapy. In contrast to conventional …

Background: Current thrombolytic therapies utilize exogenous plasminogen activators (PAs)
to effectively lyse clots, restoring blood flow, and preventing tissue and organ death. These …

Drugs that induce thrombosis in the tumour vasculature have not resulted in long-term
tumour eradication owing to tumour regrowth from tissue in the surviving rim of the tumour …

Background Ferritin, a ubiquitously distributed iron storage protein, can specifically target
tumor cells through transferrin receptor 1. Due to its rearrangeable nanocage structure …

Effective drug delivery to a tumor depends on favorable blood perfusion within the tumor. As
an important component of tumor extracellular matrix, fibrin is abundant near tumor vessels …

Most patients are at high risk of thrombosis during cancer treatment. However, the major
discrepancy in the therapeutic mechanisms and microenvironment between tumors and …

Activated platelets can maintain tumor vessel integrity, thereby leading to limited tumor
perfusion and suboptimal antitumor efficacy of nanoparticle-based drugs. Herein, to disrupt …